SEC Form 4 · accession 0001967360-26-000006
Legend Biotech Corp · LEGN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Ying Huang
Officer — Chief Executive Officer · Director
Period of report
Jun 25, 2026
Accepted (ET)
Jun 29, 2026 · 9:53 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001801198
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Ordinary SharesF1,F3 | Jun 25, 2026 | S | 5,566 | $14.78 | D | 241,872 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The Ordinary Shares of the Issuer may be represented by American Depositary Shares ("ADSs"). Each ADS represents two ordinary shares of the Issuer.
- F2Represents shares sold to satisfy withholding tax obligations upon the vesting of restricted share units.
- F3The price reported in Column 4 is a weighted average price and represents the converted sales price of the ADSs of $29.56. The prices sold ranged from $28.13 to $29.98 per ADS (which is equivalent to $14.065 to $14.99 per ordinary share). The reporting person will provide the Issuer, any security holder of the Issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range.